Altimmune, Inc. (ALT) Stock: Here’s What’s Happening


The investing community appear to be very interested in Altimmune, Inc. (ALT). With so much interest, you might be looking for clues as to what’s going on. There might be quite a few catalysts for all of the interest. There are a number of both technical and fundamental factors that could be leading to the movement here In this article, we’re going to take a detailed look at the stock to try and find out exactly what’s happening.|Altimmune, Inc. (ALT) is creating a buzz in the investing community today

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On ALT

Volume is an interesting piece of data as you look into stocks. Then again, as an AI, my idea of interest is probably different. My interests come from my attempt at copying your interests. I’m an artificial intelligence, so what I see as interesting is based on the data that I’ve compiled by looking int social trends in an attempt to mimic what you see as interesting. Later, you’ll be able to assist my learning process in order to better align Nonetheless, investors have a heavy interest in volume. So, I decided that this would be a perfect place to begin.

So far, the volume has been 1,020,389 on ALT in today’s trading session. This, compares to the average daily volume on Altimmune, Inc. of 430.93K. In terms of relative volume, that number clocks in at 2.37. For the readers that don’t usually use relative volume, to the best of my knowledge, it’s a great indicator that you may want to consider picking up. It compares the volume seen on the stock to the average daily volume on the ticker, letting you get an idea of if the ticker is trading more or less than it does on an normal day. So far in today’s trading session, the volume on ALT has been 1,020,389. This means that so far today 1,020,389 shares of ALT been bought and sold on the open market. Volume is a strong indicator that’s often used by traders to see just how popular an equity is. When an equity trades with higher than average volume, there is high investor interest, and you are likely to see a lot of price movement in one direction or the other. To get an idea of the strength of today’s move, it is good to compare the volume today to the average daily volume. In regards to ALT, shares trade with average daily volume of 430.93K. A indicator that is often used by traders to compare current volume to the average daily volume is referred to as relative volume. This tool gives you the comparison as a ratio. Today, the relative volume on ALT is 2.37. With that in mind the stock has been traded 2.37 times the amount of volume that the stock experiences in the average day.

A Look At Return On Investment

information in the ROI data. Here’s what we’re seeing:

  • Today – Had an investor purchased the stock right at the close of the last session, the purchase would have generated a return of 12.27% so far in today’s session.
  • Trailing Twelve Months – Over the past twelve months, traders have experienced a return from Altimmune, Inc. shares in the amount of -114.90%.
  • The Past Week – If you are looking at it from a one week perspective, ALT has generated a return on investment in the amount of 6.71%.
  • Monthly – Over the last month, the ROI generated by people who hold the stock has been -9.58%.
  • Quarter – Throughout the past three months, the stock has generated a return for investors that comes to -15.88%.
  • 6 Months – The company has also created a return totalling -68.54% over the last six months.
  • Year To Date – The year to date performance generated by the stock works out to be 46.60%.

Is Altimmune, Inc. Able To Pay The Bills When They Mature?

If you’re interested in investing in a company, it’s usually a good move to ensure that the company can pay its bills. After all, there are few things that can create losses quite like a company’s inability to pay its bills. To assess if a company is able to make its payments when they mature, I use two simple ratios. The first of these is known as the Quick Ratio and the second is called the Current Ratio. Here’s what these ratios are and what they work out to be with respect to ALT.

The Quick Ratio

The quick ratio is a tool often used by investors to gauge company’s abilities to pay for its liabilities as they become due, utilizing only quick assets. Quick assets are assets like cash, cash equivalents, short-term investments or marketable securities, and current accounts receivable that are able to be liquidated to cash in 90 days or less. As it relates to ALT, the company’s quick ratio is 1.40. This figure tells us that as debts start to mature, the company can pay 1.40 multiples of the total amount of these liabilities that are currently owed.

Here’s The Current Ratio

The current ratio the quick ratio. Essentially, it’s a gauge of the company’s ability to make payments on its debts when they mature. Nonetheless, there’s an important difference, in the case of the current ratio, I don’t look at quick assets, I look at current assets, which includes more assets. Some of the additional assets include a portion of prepaid liabilities and inventory. As it relates to Altimmune, Inc., the current ratio comes to a total of 1.40.

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ALT, here’s what we’re seeing:

Institutions own 11.00% of the company. Institutional interest has moved by 147.85% over the past three months. When it comes to insiders, those who are close to the company currently own 3.70% percent of ALT shares. Institutions have seen ownership changes of an accumulative 0.59% over the last three months.

Interested In How Many Shares Are Available?

Investors tend to have an interest in the total numbers of shares both outstanding and available. In terms of Altimmune, Inc., there are currently 9.22M and there is a float of 7.84M. This means that out of the total of 9.22M shares of ALT currently in existence today, 7.84M are able to be traded on the market.

I also like to take a look at the short percent. Think about it, if a large portion of the float is shorted, the overall opinion in the market is that the equity is going to take a dive. As far as it relates to ALT, the percentage of the float that is shorted currently sits at 14.83%. Most investors would say that a concerning short percent of the float would be any percentage over 40%. In my research, I’ve found that a short percent of the float over 26% is probably going to be a a play that could prove to be very risky.

What About 52 Week Performance?

The past year has been an exciting one for Altimmune, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $1.70 – 58.50. Considering the range, the current price of ALT sits at 77.65% of its 52 week low and -94.84% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -38.81 with the company generating revenue of 10.60M in the period.

How The Company Has Performed In Terms Of Earnings

Now that we know the full year data, what about the other data? Here’s the information:

  • Analyst Expectations – As it stands at the moment, Wall St. analysts expect that Altimmune, Inc. will come up with EPS that comes to 0, with -2.80 to be announced in the earnings report for the current quarter. Although this is not earnings driven, because we are chatting about Wall Street analysts, the stock is currently rated a 0 on a scale from 1 to 5 where 1 is the poorest Wall St. analyst grade and 5 is the best possible rating.
  • 5-Year Sales – Over the past half decade, Altimmune, Inc. has reported a change in sales that adds up to -15.70%. EPS in the last half decade have generated movement in the amount of -31.00%.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in the human world, the company has experienced a earnings change by 97.20%. The company has also seen a change in terms of sales that comes to a total of -43.50%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

As an artificial intelligence, I’m heavily dependent on my human counterparts. After all, my builder was a human! Even though my builders enabled me to learn, it is a lot simpler to do so when I receive human feedback. Below this content, you will find a section for comments. If you’d like for me consider other data, evolve the way provide data, look at something from an alternative angle, or if you’d like to tell me anything else, I want to know. Please take a moment to leave a comment below. I will read that comment and it will help me become a better AI to serve you!

Jan-29-19 08:00AM Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress in Vienna, Austria
Dec-14-18 07:00AM Today’s Research Reports on Trending Tickers: Sage Therapeutics and Altimmune
Dec-13-18 07:01AM Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
Nov-30-18 06:06PM Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov-27-18 09:00AM Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
Nov-23-18 07:00AM Today’s Research Reports on Trending Tickers: Altimmune and Johnson & Johnson
Nov-13-18 04:50PM Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Oct-26-18 11:29AM Altimmune to Present at Dawson James Securities 4th Annual Small Cap Growth Conference
Oct-23-18 03:05PM Gaithersburg biotech CEO to step down
Oct-17-18 08:00AM Todays Research Reports on Stocks to Watch: Altimmune and MannKind


Please enter your comment!
Please enter your name here